Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atricure Inc (NQ: ATRC )

25.26 +0.91 (+3.74%)
Streaming Delayed Price Updated: 12:04 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atricure Inc

< Previous 1 2 3 4 5 Next >
AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From AtriCure, Inc.
Via Business Wire
5 Analysts Have This to Say About AtriCure
Within the last quarter, AtriCure (NASDAQ:ATRC) has observed the following analyst ratings: 
Via Benzinga
AtriCure: Q2 Earnings Insights
AtriCure (NASDAQ:ATRC) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by... 
Via Benzinga
AtriCure Reports Second Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate at Upcoming Investor Conferences
From AtriCure, Inc.
Via Business Wire
5 Analysts Have This to Say About AtriCure
Over the past 3 months, 5 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
AtriCure to Announce Second Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
Analyst Ratings for AtriCure
Over the past 3 months, 4 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial
From AtriCure, Inc.
Via Business Wire
AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer
From AtriCure, Inc.
Via Business Wire
AtriCure's Q1 EPS Miss Estimates, Needham Lowers Price Target
Needham lowered AtriCure Inc's (NASDAQ: ATRC) price target to $67 from $79 due to peer multiple compression, with the Buy rating unchanged. 
Via Benzinga
4 Analysts Have This to Say About AtriCure
Over the past 3 months, 4 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
AtriCure: Q1 Earnings Insights
AtriCure (NASDAQ:ATRC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by... 
Via Benzinga
AtriCure Reports First Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure Launches EnCompass® Clamp, a part of Isolator Synergy™ Ablation System
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce First Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Deeper Losses In Q4 Despite 27% Jump In Sales, Issues FY22 Guidance
AtriCure Inc (NASDAQ: ATRC) reported Q4 
Via Benzinga
Recap: AtriCure Q4 Earnings
AtriCure (NASDAQ:ATRC) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings... 
Via Benzinga
AtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results
From AtriCure, Inc.
Via Business Wire
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... 
Via Benzinga
Earnings Scheduled For February 15, 2022
Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion. 
Via Benzinga
A Preview Of AtriCure's Earnings
AtriCure (NASDAQ:ATRC) is set to give its latest quarterly earnings report on Tuesday, 2022-02-15. Here's what investors need to know before the announcement. Analysts estimate that AtriCure will... 
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
AtriCure Publishes Inaugural ESG Report
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Fourth Quarter and Full Year 2021 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.